Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral versus sublingual estradiol crossover study in transgender women
ACTRN12625000730404Phase 4Not yet recruiting
- Sponsor
- Monash Health
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of estradiol and estradiol valerate in gender dysphoria (GD) (2 arms), sponsored by Monash Health. Primary endpoint: Primary: coagulation profile composite outcome. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
estradiolestradiol valerate
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on ACTRN12625000730404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000730404.